Pfizer has announced plans to acquire Canadian drug developer Trillium Therapeutics Inc. in a $2.26 billion deal meant to boost Pfizer’s arsenal of blood cancer therapies.
Under the deal, announced in an Aug. 23 press release, Pfizer will buy all outstanding Trillium shares at $18.50 apiece, representing a 118 percent premium on the stock’s 60-day weighted average price. In 2020, Pfizer acquired a $25 million stake in Trillium.
